Shares of Moderna dropped 5.58% to $146.41 at 14:48 EST on Tuesday, following yesterday's downward trend. The Nasdaq Stock Market is jumping 1.01% to $12,566.20, following yesterday's upward trend, This seems, so far, an all-around positive trend exchanging session today.
Moderna's last close was $155.07, 21.92% below its 52-week high of $178.50.
News about Moderna today
Take-two, occidental petroleum, Moderna: what to watch when the stock market opens today. According to today's article on The Wall Street Journal, "-Shares of the vaccine maker Moderna were down 1% premarket. "
Moderna vaccine found safe, effective ahead of key FDA review. According to today's article on Bloomberg Quint, "Moderna's vaccine will be distributed to sites around the country where health-care workers and residents of long-term care facilities, such as nursing homes, are expected to get the earliest doses.", "Once the U.S. grants authorization, advisers to the Centers for Disease Control and Prevention must meet, as they did last week on Pfizer's vaccine, to give Moderna's shot the green light and provide offer specific recommendations for use and monitoring. "
Moderna vaccine found safe, effective before key FDA review. According to today's article on Bloomberg Quint, "Moderna Inc.'s vaccine is safe and effective for preventing Covid-19 in people ages 18 and older, U.S. regulators said, clearing the way for a second shot to quickly gain emergency authorization and add to the country's sprawling immunization effort.", "The FDA staff's analysis of Moderna's trial data found 11 cases of Covid-19 in the group that received the vaccine and 185 in those that got a placebo instead."
Moderna shares up in premarket as FDA calls Covid-19 vaccine 'highly effective'. According to today's article on MarketWatch, "Shares of Moderna Inc. gained 1.5% in premarket trading on Tuesday after the Food and Drug Administration said the company's COVID-19 vaccine candidate is "highly effective" at preventing infections with the coronavirus. "
Canada to receive early access to Moderna Covid-19 vaccine. According to today's article on Business Insider, "Moderna submitted an application for regulatory review of its COVID-19 vaccine candidate under Health Canada's interim order on October 12, 2020. ", "The logistical planning for the delivery of Moderna doses is complete, and shipments to Canada could begin within 48 hours of regulatory approval."
Moderna's Sales
Moderna's sales growth is 1428.1% for the ongoing quarter and 13065.3% for the next. The company's growth estimates for the current quarter is a negative 48.6% and positive 565.7% for the next.
Moderna's Revenue
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna's Stock Top and Bottom Yearly Value
Moderna's stock is valued at $146.41 at 14:48 EST, way below its 52-week high of $178.50 and way higher than its 52-week low of $17.68.
Moderna's Moving Average
Moderna's worth is way above its 50-day moving average of $106.15 and way above its 200-day moving average of $77.98.Previous days news about Moderna
Moderna offers U.S. fail-safe on vaccines if Pfizer falls short. According to Bloomberg Quint on Thu Dec 10, "While Jordan declined to comment on any talks that might be ongoing now with the U.S., it could be advantageous for Moderna to find out sooner rather than later how many more doses the U.S. wants. ", ""The U.S. Supply Agreement provides the U.S. Government with four additional and separate options to purchase 100 million doses per option of mRNA-1273," Moderna said in the filing earlier this year. "
Moderna says U.S. to buy 100 million additional vaccine doses. According to Bloomberg Quint on Fri Dec 11, "As part of Operation Warp Speed, the U.S. initiative to rapidly develop and secure vaccines for Covid-19, the U.S. has the option to buy another 300 million doses from Moderna at a fixed price of $16.50 per shot, the company said. ", "HHS and the Department of Defense have provided $3.2 billion to expand the manufacturing capacity reserved for Moderna's two-dose vaccine regimen, known as mRNA-1273."